Reported Standalone quarterly numbers for GlaxoSmithKline Pharmaceuticals are:Net Sales at Rs 799.11 crore in December 2022 down 1.1% from Rs. 807.98 crore in December 2021.
Quarterly Net Profit at Rs. 164.03 crore in December 2022 up 9.62% from Rs. 149.63 crore in December 2021.
EBITDA stands at Rs. 251.40 crore in December 2022 up 21.36% from Rs. 207.16 crore in December 2021.
GlaxoSmithKline EPS has increased to Rs. 9.68 in December 2022 from Rs. 8.83 in December 2021.
GlaxoSmithKline shares closed at 1,240.15 on February 07, 2023 (NSE) and has given -14.08% returns over the last 6 months and -21.53% over the last 12 months.
| GlaxoSmithKline Pharmaceuticals | | Standalone Quarterly Results | in Rs. Cr. |
|
| Dec'22 | Sep'22 | Dec'21 | | Net Sales/Income from operations | 799.11 | 905.61 | 807.98 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 799.11 | 905.61 | 807.98 | | EXPENDITURE | | Consumption of Raw Materials | 43.12 | 117.39 | 106.98 | | Purchase of Traded Goods | 124.62 | 214.42 | 213.79 | | Increase/Decrease in Stocks | 114.77 | 20.00 | -10.47 | | Power & Fuel | -- | -- | -- | | Employees Cost | 152.99 | 141.94 | 142.39 | | Depreciation | 16.41 | 16.36 | 17.87 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 135.81 | 154.94 | 158.63 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 211.39 | 240.56 | 178.79 | | Other Income | 23.60 | 22.16 | 10.50 | | P/L Before Int., Excpt. Items & Tax | 234.99 | 262.72 | 189.29 | | Interest | 0.09 | 0.39 | 0.58 | | P/L Before Exceptional Items & Tax | 234.90 | 262.33 | 188.71 | | Exceptional Items | -11.37 | -- | -17.92 | | P/L Before Tax | 223.53 | 262.33 | 170.79 | | Tax | 59.50 | 68.77 | 33.23 | | P/L After Tax from Ordinary Activities | 164.03 | 193.56 | 137.56 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | 12.07 | | Net Profit/(Loss) For the Period | 164.03 | 193.56 | 149.63 | | Equity Share Capital | 169.41 | 169.41 | 169.41 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 9.68 | 11.42 | 8.83 | | Diluted EPS | 9.68 | 11.42 | 8.83 | | EPS After Extra Ordinary | | Basic EPS | 9.68 | 11.42 | 8.83 | | Diluted EPS | 9.68 | 11.42 | 8.83 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
